WANY
NKTR icon

Wealthspire Advisors (New York)’s Nektar Therapeutics NKTR Stock Holding History

Wealthspire Advisors (New York)’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-9
Closed -$4K – 542
2018
Q4 		$4K Buy
+9
New +$5.43K ﹤0.01% 686

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wealthspire Advisors (New York)'s NKTR Position: Q1 2019 in Review

Wealthspire Advisors (New York) sold out of Nektar Therapeutics (NKTR) in Q1 2019, closing a stake of 9 shares — an estimated $4K sold.

Wealthspire Advisors (New York) first reported a position in NKTR in Q4 2018 and held it in 1 quarter. The position peaked at $4K in Q4 2018. 350 funds tracked by Wall St. Rank hold NKTR as of Q1 2019.

  • Wealthspire Advisors (New York) reported no remaining Nektar Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 9 Nektar Therapeutics shares in Q1 2019, an estimated $4K.
  • Wealthspire Advisors (New York) first reported a position in Nektar Therapeutics in Q4 2018 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Nektar Therapeutics position peaked at $4K in Q4 2018.
  • 350 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2019.

Based on Wealthspire Advisors (New York)'s 13F filing for Q1 2019, filed 8 May 2019.